Champions Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended April 30, 2022
July 22, 2022 at 01:29 am IST
Share
Champions Oncology, Inc. reported earnings results for the fourth quarter ended April 30, 2022. For the fourth quarter, the company reported net loss was USD 0.344 million compared to USD 0.481 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.03 compared to USD 0.04 a year ago.
Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Companyâs TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.
CHAMPIONS ONCOLOGY, INC. 
